Forrest Jespersen, MD
Pulmonary Disease · Coeur D Alene, IDNPI 1245659143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AstraZeneca at 31.2% of the total. Reporting peaked in 2023 at $295 and has fallen 65.7% since, to $101 in 2025.
Across 8 payments — averaging $104.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$262
- Inari Medical, Inc.$217
- AbbVie$123
- Genentech USA, Inc.$115
- Shionogi Inc$105
- United Therapeutics Corporation$16
What the payments were for
- Food & beverage$839100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $262 |
| Inari Medical, Inc. | 1 | $217 |
| AbbVie | 1 | $123 |
| Genentech USA, Inc. | 1 | $115 |
| Shionogi Inc | 1 | $105 |
| United Therapeutics Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$217
- CT THROMBECTOMY SYSTEM KIT$217
- AVYCAZ$123
- Fetroja$105
- TEZSPIRE$101
How this compares
$839 in reported general payments places this provider in the 65th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 14 | $311,927 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $85,175 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $65,664 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 85 | $64,848 |
| Dupixent SyringeDupilumab | 14 | $50,989 |
| Dupixent PenDupilumab | 11 | $40,566 |
| Spiriva HandihalerTiotropium Bromide | 31 | $25,972 |
| Spiriva RespimatTiotropium Bromide | 35 | $23,969 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $11,139 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,891 |
| Serevent DiskusSalmeterol Xinafoate | 12 | $7,158 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $7,109 |
| Varenicline Tartrate | 21 | $5,770 |
| Pulmicort FlexhalerBudesonide | 16 | $5,038 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $3,809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort | $262 | $73,966123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Coeur D Alene
- Todd HoopmanCoeur D Alene$76K
- Robert ScogginsCoeur D Alene$2K
- Jeannette Zinggeler BergCoeur D Alene$1K
- Amanda LiggettCoeur D Alene$977
- Kevin ChangCoeur D Alene$905
- David YorkCoeur D Alene$757
- Chad BrizendineCoeur D Alene$268
- Elizabeth HankinsonCoeur D Alene$0
- Allen SalemIdaho Falls$44K
- Mark RasmusBoise$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.